ATAD4 Inhibitors
ATAD4 inhibitors are a class of chemical compounds that specifically target and regulate the function of the ATAD4 protein, a member of the ATPases Associated with diverse cellular Activities (AAA+) family. ATAD4 is involved in processes requiring energy-dependent remodeling of macromolecular structures, such as protein degradation, DNA repair, and chromatin remodeling. As an ATPase, ATAD4 hydrolyzes ATP to provide the necessary energy for these complex cellular processes. By doing so, it helps maintain the stability of various intracellular functions that are essential for cellular homeostasis. The inhibition of ATAD4 can disrupt these activities, particularly those related to the ATP-dependent structural modifications of proteins and nucleic acids.
Inhibitors of ATAD4 are designed to interfere with the protein's ATPase activity, often by competing for ATP binding at the catalytic site or by altering the conformational changes required for ATP hydrolysis. This inhibition may prevent the proper assembly or disassembly of protein complexes that depend on ATAD4 for their function. The design and optimization of ATAD4 inhibitors involve a combination of structural biology, molecular modeling, and chemical synthesis approaches. Researchers focus on understanding the detailed molecular architecture of ATAD4 to identify key regions critical for its activity. These studies typically use techniques like X-ray crystallography or cryo-electron microscopy to map out the binding interactions between the protein and potential inhibitors. Through these efforts, specific small molecules can be engineered to selectively modulate ATAD4 activity while maintaining precise control over their biochemical effects within the cellular environment.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Ouabain-d3 (Major) | sc-478417 | 1 mg | $516.00 | |||
Ouabain specifically inhibits Na+/K+-ATPases. By binding to this ATPase, it disrupts ion balance across the plasma membrane. Potential effects on ATAD4 might be related to cellular ionic imbalances and subsequent signaling alterations. | ||||||
Sodium azide | 26628-22-8 | sc-208393 sc-208393B sc-208393C sc-208393D sc-208393A | 25 g 250 g 1 kg 2.5 kg 100 g | $43.00 $155.00 $393.00 $862.00 $90.00 | 8 | |
Azide is a general ATPase inhibitor and works by preventing the hydrolysis of ATP. Its influence on ATAD4 might be due to general energy disruption in the cell, possibly affecting cellular processes relying on ATP hydrolysis. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin specifically inhibits the Sarco/Endoplasmic Reticulum Ca2+ ATPase (SERCA), disrupting calcium homeostasis in the cell. Effects on ATAD4 may be indirectly due to altered calcium signaling. | ||||||
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $98.00 $255.00 $765.00 $1457.00 | 280 | |
Bafilomycin A1 targets V-type proton ATPases, inhibiting acidification of intracellular compartments. If ATAD4 plays roles in processes relying on these compartments, its function could be indirectly affected. | ||||||
N-Ethylmaleimide | 128-53-0 | sc-202719A sc-202719 sc-202719B sc-202719C sc-202719D | 1 g 5 g 25 g 100 g 250 g | $22.00 $69.00 $214.00 $796.00 $1918.00 | 19 | |
N-Ethylmaleimide inhibits several ATPases through covalent modification of cysteine residues. Its effect on ATAD4 might be due to alteration of its ATP-binding or hydrolysis capability. | ||||||
Furosemide | 54-31-9 | sc-203961 | 50 mg | $41.00 | ||
Furosemide primarily inhibits the Na+/2Cl-/K+ cotransporter but also has effects on some ATPases. Any impacts on ATAD4 might arise from alterations in cellular ionic balances. | ||||||
Oligomycin A | 579-13-5 | sc-201551 sc-201551A sc-201551B sc-201551C sc-201551D | 5 mg 25 mg 100 mg 500 mg 1 g | $179.00 $612.00 $1203.00 $5202.00 $9364.00 | 26 | |
Oligomycin A targets the ATP synthase complex, inhibiting mitochondrial ATP production. Effects on ATAD4 might be indirectly due to disruptions in cellular energy balance. | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $155.00 $525.00 | ||
Monensin inhibits Na+/H+ antiport ATPase, affecting cellular pH and ion balance. Its influence on ATAD4 might be through disruptions in these balances or secondary signaling effects. | ||||||
Concanamycin A | 80890-47-7 | sc-202111 sc-202111A sc-202111B sc-202111C | 50 µg 200 µg 1 mg 5 mg | $66.00 $167.00 $673.00 $2601.00 | 109 | |
Concanamycin A inhibits V-type proton ATPase, similar to Bafilomycin A1, affecting intracellular compartment acidification. Its potential impact on ATAD4 could arise from processes relying on these compartments. | ||||||
Emodin | 518-82-1 | sc-202601 sc-202601A sc-202601B | 50 mg 250 mg 15 g | $105.00 $214.00 $6255.00 | 2 | |
Emodin inhibits Na+/K+-ATPase, disrupting the ion balance across membranes. Its influence on ATAD4 could be linked to altered cellular ionic balances or subsequent signaling. | ||||||